ANDA 85418, held by Hikma. Butabarbital Sodium.
As of Nov 16, 2026, ANDA 85418 (Sodium Butabarbital), held by Hikma, was first approved by FDA on Aug 15, 1977, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 15, 1977 | Original application | Approved | None posted |
| Sodium Butabarbital15MG · tablet;oral | Butabarbital Sodium | Discontinued |
| Sodium Butabarbital30MG · tablet;oral | Butabarbital Sodium | Discontinued |
| Aug 7, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 7, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| Mar 28, 1991 | Supplement 9Manufacturing | Approved | None posted |
| Aug 4, 1989 | Supplement 8Labeling | Approved | None posted |
| Mar 16, 1988 | Supplement 7Labeling | Approved | None posted |
| Nov 8, 1982 | Supplement 4Manufacturing | Approved | None posted |
| Aug 15, 1977 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters